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Abstract. Background. Thrombin is a key enzyme in throm- 
bogenesis. In animals, specific antithrombotic herapy at the 
time of coronary angioplasty reduced the incidence of sub- 
acute occlusion and inhibited the restenosis response. Arga- 
troban is a highly selective synthetic thrombin antagonist 
that binds in a competitive manner. This is a report of a 
dose-verification study, assessing the safety and feasibility of 
intravenous Argatroban administration in patients undergo- 
ing percutaneous transluminal coronary angioplasty. Meth- 
ods. Before angioplasty an intravenous bolus of 30 ~Lg/kg ar- 
gatroban was administered, followed by a continuous 
infusion of 3.5 ~Lg/kg/min for 72 hours. Bolus injection was 
repeated, and the infusion rate was increased in order to 
achieve an activated coagulation time (ACT) of over 300 sec- 
onds. Following interim analysis, the bolus and initial infu- 
sion rate for the subsequent treatment groups was deter- 
mined. Study endpoints were the occurrence of adverse 
events, coagulation tests, and qualitative angiogram reading. 
Patients were monitored by continuous 12-lead electrocardio- 
graphic recording over 24 hours, and underwent control angi- 
ography 18-24 hours following angioplasty. Results. Four 
treatment groups, comprised of 2, 8, 9, and 11 patients, re- 
spectively, were studied. The first two patients were excluded 
from analysis, since the initial dose was ineffective to attain 
an ACT-authorizing coronary angioplasty. The group with 
the highest dosage received a 250 ~tg/kg intravenous bolus of 
argatroban, followed by a 4 hour infusion of 15 pLg/kg/min. 
At 4 hours the infusion rate was lowered to 3.8 ~tg/kg/min and 
was continued for 68 hours without adjustment for catheter 
removal. The adverse vent profile included myocardial in- 
farction, aortocoronary b pass graft, bailout procedures, and 
repeat coronary angioplasty. Thrombin-time (TT), activated 
partial thromboplastin ime (APTT), and prothrombin time 
(PT) were significantly related to argatroban plasma concen- 
tration, as demonstrated by regression analyses (R-square 
0.64, 0.71, and 0.84, respectively). Prothrombin fragments 1 
and 2 and thrombin-antithrombin III complex did not fit into 
a mathematical model, but showed slightly increased levels 
after reduction or cessation of the infusion rate. Conclusions. 
This dose-verification study, including 30 patients at four 
dose levels, indicated that argatroban i fusion in coronary 
angioplasty patients can be administered safely, and results 
in an adequate and predictable vel of anticoagulation. 
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Ang iop lasty  of coronary narrowings greatly enlarges 
the arterial lumen. Nevertheless, the short-term ther- 
apeutic benefit of percutaneous transluminal  coronary 
angioplasty (PTCA) can be limited by formation of 
mural thrombus and subsequent abrupt closure of the 
coronary artery. In addition, organization of mural 
thrombus and proliferation of smooth muscle cells lead 
to vessel restenosis, also adversely influencing me- 
dium- and long-term results. The central role of 
thrombin in these events is a result of its effects on 
the clotting cascade, leading to fibrin and thrombus 
formation; on platelet aggregation, causing the libera- 
tion of growth factors; and finally its direct mitogenic 
effect on smooth muscle cells [1]. A low thrombin level 
is sufficient to activate phospholipid membrane bound 
factor V, which is part of the prothrombinase com- 
plex, and can therefore strongly accelerate thrombin 
formation [2]. Interference with this positive feedback 
loop by potent and specific thrombin inhibition is a 
very effective antithrombotic strategy [3,4]. 
Argatroban, (2R,4R)-4-methyM-[N 2-(3-methyl-i, 
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2,3,4- tetrahydro- 8 quinolonyl) sulphonyl) - arginyl] - 2- 
piperidine carboxylic acid), is an arginine derivate that 
binds competitively to thrombin [5]. Compared with 
heparin, it has several potential advantages. Argatro- 
ban is synthetic and therefore has no natural inhibi- 
tors. It does not need antithrombin III as a cofactor, 
and it is non-antigenic. Heparin is a mixture of heter- 
ogenous ized depolymerized molecules, and therefore 
its bioactivity may vary depending on the particular 
lot. In contrast, the anticoagulant effect of argatroban 
is concentration dependent [6] and comprises both 
free and clot-bound thrombin. 
Specific antithrombin therapy using argatroban has 
been shown to be superior to heparin treatment in 
numerous experimental animal models of arterial 
thrombogenesis [7-19]. At doses causing comparable 
prolongation of activated partial thromboplastin time 
(aPTT), argatroban has been demonstrated to be sig- 
nificantly more effective than heparin for the preven- 
tion of platelet-rich thrombotic occlusion in an animal 
model [20]. Several human trials with argatroban 
have been completed using dosage regimens up to 25 
mg/hr IV for 2 hours [21] or 20 mg/hr IV for 2 hours 
after a 10 mg bolus [22]. These studies have demon- 
strated a moderate dose-dependent 4.5-fold increase 
in thrombin time and a 1.6-fold prolongation of aPTT, 
with no effect of concomitant aspirin administration. 
The doses administered in human studies were low 
compared with those used in animal models, and at 
these low doses the elimination half-life is 24 minutes 
[23]. Based on these findings, it was felt safe to inves- 
tigate this drug in patients with a hypercoaguable con- 
dition, such as patients with unstable angina or under- 
going PTCA. 
Recently argatroban was infused over 4 hours in 
patients experiencing unstable angina pectoris [24]. 
Infusion of the drug (0.5-5.0 ~g/kg/min) resulted in 
a dose-dependent i crease in the aPTT and effectively 
prevented recurrences of ischemic episodes. Notably, 
9 out of 43 patients experienced an episode of unstable 
angina shortly after drug administration was termi- 
nated. The authors attributed this to a rebound phe- 
nomenon. 
There has been limited experience with the use of 
argatroban in PTCA patients (Fitzgerald, data not 
published). In this study, 12 patients were random- 
ized to receive either a bolus of 30 ~g/kg argatroban, 
followed by an intravenous infusion of 2 ~g/kg/min 
over 2 hours, or a bolus injection of 10,000 IU of hepa- 
rin and a subsequent 4 hour infusion of 1000 IU/hr. 
In order to further define the optimal dose of argatro- 
ban for patients undergoing coronary angioplasty, the 
pre-Argaplasty trial was initiated. This dose-veri- 
fication study was undertaken to assess the safety and 
feasibility of administration of argatroban i  patients 
undergoing balloon angioplasty and to broaden our un- 
derstanding of the response to the coagulation system 
to this agent. 
Methods  
Study design 
This study was an open, nonrandomized ose- 
verification study, carried out in three hospitals in the 
Netherlands. The study was conducted according to 
G.C.P. regulations. Patients were allocated to study 
medication after giving written, informed consent. 
This study assessed the safety and feasibility of the 
use of three different doses of argatroban (groups A, 
B, and C, respectively) in patients undergoing PTCA. 
Acetylsalicylate (250 mg intravenous) was adminis- 
tered just prior to angioplasty, and 160 mg acetylsalic- 
ylate was administered orally for the next 3 days. 
Patient selection 
Patients with stable or unstable angina pectoris due 
to one or more angiographically significant lesions in 
the native coronary system amenable to balloon angio- 
plasty were considered eligible for this study. The 
main exclusion criteria were acute myocardial in- 
farction or thrombolytic therapy within 2 weeks prior 
to PTCA; current reatment with oral anticoagulant 
drugs; and history of peptic ulcer disease, upper gas- 
trointestinal bleeding, or stroke. 
Coronary angiograms and angioplasty 
Coronary angiograms were obtained immediately be- 
fore and after balloon angioplasty, and repeated 18-24 
hours afterwards. To standardize the method of data 
acquisition and to ensure the exact reproducibility of 
the angiograms performed after the intervention and 
at follow-up, measures were taken as described ear- 
lier [25,26]. Choice of angioplasty device, balloon pres- 
sure, and duration of inflation were left to the discre- 
tion of the operator. All angiograms were read at 
Cardialysis B.V., Rotterdam, the Netherlands. 
Argatroban dose regimen and 
dose adjustment 
Argatroban was provided by SynthSlabo Recherche 
(L.E.R.S.), Bagneux CSdex, France. Its clearance 
and half-life are 5.0 +- 0.5 ml/kg/min and 24.4 +_ 3.5 
minutes, respectively, in healthy volunteers. As arga- 
troban is a photosensitive drug, it was dispensed in 
opaque ampules containing doses 0.5 mg/ml. The max- 
imum total daily authorized ose was 10 mg/kg body 
weight. 
The first eight patients (group A) were to receive 
a bolus of 30 ~g/kg argatroban, followed by a 3.5 ~Lg/ 
kg/min infusion over the next 72 hours. When the acti- 
vated clotting time (ACT) exceeded 300 seconds, an- 
gioplasty was authorized approximately 45 minutes 
after administration ofthe bolus and the start of arga- 
troban infusion. For an ACT less than 300 seconds, 
an extra 30 ~Lg/kg bolus was administered, and the 
rate of infusion was increased by 0.5 ~Lg/kg/min incre- 
ments until the ACT exceeded 300 seconds. Following 
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PTCA, the infusion rate was adjusted to maintain the 
aPTT between 100 and 120 seconds (2.5-3 times nor- 
mal value) according to the adjustment algorithm 
shown in Table 1. Following interim analysis, the bo- 
lus and initial infusion rates for the adjacent reat- 
ment groups (group B and C) were determined. 
The femoral sheath was removed after reduction of 
the infusion rate to a predetermined level of 2.0 ~g/ 
kg/min, in order to obtain an aPTT of less than 80 
seconds (less than twice normal value). One hour after 
sheath removal, infusion rates were restored to their 
previous etting. The patients were kept on strict bed 
rest for the next 24 hours. 
Study endpoints; evaluation of efficiency and safety 
Study endpoints were the occurrence of major ad- 
verse cardiac events and bleeding complications, elec- 
trocardiographic changes as detected by continuous 
12-lead recording, coagulation test results, and quali- 
tative angiogram interpretation. Safety was evalu- 
ated on the basis of occurrence of death, nonfatal myo- 
cardial infarction, revascularization procedures, and 
bleeding complications. All deaths were considered 
cardiac unless documented to the contrary. Myocar- 
dial infarction was diagnosed on the basis of new Q 
waves (Minnesota Code [27]) or an increase in creati- 
nine kinase of more than twice the upper limit of nor- 
mal with a concomitant increase in myocardial bound 
fraction. 
Bailout stenting was considered equivalent to coro- 
nary artery bypass grafting (CABG) if patency of the 
target vessel could not be maintained otherwise. If  a 
stent was implanted electively after the initial angio- 
plasty (i.e., not comprising a bailout procedure), this 
was considered to be equivalent to repeat angioplasty. 
Repeat angioplasty was defined as re-insertion of a 
guiding catheter followed by angioplasty at the previ- 
ously dilated site. The occurrence of typical anginal 
symptoms or electrocardiographic evidence of myo- 
cardial ischemia at rest or during exercise in case of 
atypical anginal symptoms and an angiographic diam- 
eter stenosis of >50% by visual inspection was re- 
quired to justifty repeat angioplasty or bypass sur- 
gery. Bleeding was classified as major if it was overt 
and led to a hemoglobin fall of at least 5 g/dl or 15% 
hematocrit; required transfusion of five or more units 
of whole blood or packed cells; or occurred intracran- 
ial, retroperitoneal, or into a major joint [28]. Minor 
bleeding was defined as overt, gross hematuria, or 
haematemesis, or if it led to a fall in haemoglobin of 
at least 3 g/dl, or at least 10% hematocrit. Hematuria 
was classified as macroscopic when clinically evident, 
and as microscopic in the presence of more than four 
erythrocytes per high-power field. 
Secondary endpoints 
Coronary angiograms were analyzed for TIMI flow 
assessment [29], as documented at recatheterization 
Table 1. Argatroban adjustments after the angioplasty 
procedure according to aPTT values 
aPTT (sec)  Discontinuation 
x normal (duration Dose change in 
value (NV) in rain) (~g/kg/hr) 
<80 sec - -  + 1 ~g/kg/min I" 
<2 times NV 
80-100 sec - -  +0.5 ~g/kg/min 
2-2.5 times NV 
101-120 sec - -  No change 
2.5-3.0 times NV 
121-140 sec - -  -0.5 ~g/kg/min $ 
3.0-3.5 times NV 
141-160 sec 15 rain -1 ~g/kg/min $ 
3.5-4.0 times NV 
>160 sec 30 min -2 ~g/kg/min $ 
>4 times NV 
24 hours following balloon angioplasty. Continuous 12- 
lead electrocardiography over 24 hours was analyzed 
for inschemic episodes of recurrent ischemia, defined 
as at least 0.1 mV ST-segment elevation for at least 1 
minute. Finally, blood samples were taken at various 
points in time to assess the dose-response r lationship 
of various coagulation parameters. Determination of 
ACT was done extemporaneously in the catheteriza- 
tion laboratory on whole blood samples. Bleeding time 
was performed at screening, 12 hours, and 72 hours 
after commencement of the study medication. Blood 
samples for activated partial thromboplastin time 
(APTT), prothrombin time (PT), thrombin time (TT, 
thrombin concentration 4-20 IU/ml), thrombin- 
antithrombin-complex (TAT), and prothrombin frag- 
ments 1 and 2 (Fi. ~) were drawn in the arm contralat- 
eral to that receiving medication. Those samples were 
centrally assessed in a hemostasis core lab. 
Statistical analysis 
Mainly descriptive statistics were carried out. Contin- 
uous variables were expressed as medians with their 
range, while categoric variables were expressed as 
absolute numbers and percentages. Two patients 
(group A) were not included in the statistical analysis, 
since the initial dose regimen, as specified in the pro- 
tocol, was ineffective in terms of ACT. Regression 
analyses of the different coagulation parameters on 
argatroban plasma levels were performed. Linear 
models were fitted and expanded with a logarithmic, 
square, or cubic term. 
Results 
Patient population and dose regimen 
The first two patients (group A) enrolled in the trial 
received a bolus of 30 ~g/kg argatroban followed by 
an infusion of a rate of 3.5 ~g/kg/min in order to ob- 
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tain an ACT balloon angioplasty of 300 seconds. How- 
ever, despite repeated bolus injections and multiple 
increases in the infusion rate to 5.0 ~g/kg/min, the 
ACT level did not exceed 200 seconds. Medication in 
these patients was replaced by routine (i.e., heparin) 
treatment. 
Following detailed review of the first two patients, 
the next dosage group (group B) was assigned to re- 
ceive a bolus of 60 ~g/kg, followed by a 4 hour infusion 
of 8 ~g/kg/min. At 4 hours the infusion rate was low- 
ered to 4 ~g/kg/min and was continued for 68 hours, 
so that the maximum daily dose would not be ex- 
ceeded. In the absence of bleeding, no dosage adjust- 
ments were made. After recatheterization, the infu- 
sion rate was transiently reduced for catheter removal 
to 2.0~g/kg/min, to achieve an aPTT level of less than 
twice the normal value. One hour after sheath re- 
moval, the infusion rate was restored. Eight patients 
were treated according to this schedule. Bleeding was 
not observed, ACT increased only moderately, and 
based on the results of F1. 2 and TAT, a higher adminis- 
tration level was investigated. 
In parallel with a phase I study carried out in nine 
healthy volunteers (unpublished ata), the third dos- 
age group (group C) received a bolus of 250 ~g/kg, 
followed by a 4 hour infusion of 10 ~g/kg/min. At 4 
hours the infusion rate was lowered to 3.8 ~g/kg/min 
and was continued for 68 hours. This dosage group 
comprised nine subjects. For sheath removal the same 
procedure was followed as in the foregoing patients. 
Evaluation of clinical data indicated satisfying safety 
levels, as bleeding was not observed. Furthermore, 
hemostatic parameters revealed that at 45 minutes 
thrombin generation was not totally controlled, and 
that reduction of the infusion rate to 2 ~g/kg/min for 
the sheath removal was accompanied by increased 
thrombin conversion and activity. Interim analysis 
demonstrated that the aPTT level, at an infusion rate 
of 3.8 ~g/kg/min, was around twice the normal value. 
Based on these data, the patients in the fourth dosage 
group (group D) received a bolus of 250 ~g/kg, fol- 
lowed by a 4 hour infusion of 15 ~g/kg/min. At 4 hours 
the infusion rate was lowered to 3.8 ~g/kg/min and 
was continued for 68 hours without adjustment for 
catheter removal. This dosage regimen group was 
comprised of 11 patiets who received a total daily dose 
of 8.4 mg/kg. Demographic, linical, and angiographic 
data of the patients tudied are summarized in Tables 
2 and 3, respectively. None of the patients had a his- 
tory of bleeding or stroke. The small number of pa- 
tients does not allow for comparison of the groups; 
however, the strict inclusion criteria ensure that they 
are very similar. 
Studg endpoints (Table 4) 
In group B, one patient experienced insignificant 
bleeding at the puncture site 7 hours after sheath re- 
moval during a 4 ~g/kg/min infusion, and therefore 
the study medication was discontinued. One case of 
Table 2. Demographic data on the studied population per 
dosage group 
Group B Group C Group D 
(N = 8) (N = 9) (N = 11) 
Male gender 6 (75%) 5 (56%) 6 (55%) 
Caucasian 7 (88%) 9 (100%) 11 (100%) 
Age (range) 53 (37-70) 57 (33-74) 59 (49-77) 
Weight (range) 76 (62-105) 65 (60-85) 72 (56-92) 
Previous MI 2 (25%) 2 (22%) 5 (45%) 
Previous PTCA 1 (13%) 5 (56%) 5 (45%) 
Previous CABG 0 (0.0%) 1 (11%) 1 (9%) 
Hypertension 3 (38%) 5 (56%) 4 (36%) 
NIDDM 0 (0.0%) 2 (22%) 1 (9%) 
Hypercholesterolemia 3 (38%) 4 (44%) 2 (18%) 
Current smoker 2 (25%) 1 (11%) 2 (18%) 
Stable angina 4 (50%) 6 (67%) 6 (55%) 
Unstable angina [40] 4 (50%) 3 (33%) 5 (45%) 
Class I 0 1 3 
Class II 4 2 1 
Class III 0 0 1 
Two-vessel disease 1 (12%) 2 (22%) 2 (18%) 
Categorical variables are presented inabsolute values and percent 
N (%). 
M I  = myocardial infarction; PTCA = percutaneous transluminal 
coronary angiography; CABG = coronary artery bypass graft sur- 
gery; N IDDM = non-insulin dependent  diabetes mellitus; unstable 
angina class I-III = according to the Braunwald  classification [40]. 
phlebitis at the site of the indwelling infusion needle 
was reported, which occurred 58 hours after the com- 
mencement of the study medication. 
In treatment group C, two patients had a failed 
PTCA (one of which was a total occlusion before the 
attempt), and after discontinuation ofargatroban i fu- 
sion were referred for elective bypass surgery. An- 
other patient showed recurrent stenosis (>50%) with 
thrombus at the 24 hour control angiogram. Repeat 
PTCA (under argatroban therapy) was successful. In 
this group no bleeding complications were observed. 
In treatment group D, one patient experienced a 
myocardial infarction due to a subacute reocclusion. 
Repeat PTCA was attempted but not successful. An- 
other patient showed recurrent stenosis (>50%) on 
the 24 hour control angiogram. Repeat PTCA was not 
satisfactory, and a stent was implanted and argatro- 
ban was replaced with routine anticoagulants. During 
treatment with heparin and acenocoumarol, this pa- 
tient had prolonged epistaxis, necessitating blood 
transfusion. A second repeat PTCA was performed in 
this patient for occlusion at the stented segment. In 
addition, a false aneurysm was reported in one pa- 
tient, and prolonged insignificant bleeding at the 
puncture site in another. 
There were no reported eath or cases of hematu- 
ria in any of the four dose groups. Results of TIMI 
flow assessment and 12-1ead electrocardiographic 
monitoring are reported in Tables 3 and 4, respec- 
tively. The low number of patients enrolled does not 
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Table 3. Qualitative angiographic data on the studied 
population per dosage group 
Treatment group Group B Group C Group D 
(No. lesions) (N = 9) (N = 10) (N = 13) 
Restenotic lesion 1 (11%) 4 (40%) 4 (31%) 
Total occlusion 2 (22%) 1 (10%) 1 (8%) 
Type of lesion (AHA/ 
ACC) 
Type A 1 (11%) 1 (10%) 1 (8%) 
Type B1 3 (33%) 0 4 (30%) 
Type B2 5 (56%) 9 (90%) 7 (54%) 
Type C 0 0 1 (8%) 
TIMI flow 
post-PTCA 
TIMI0 0 1 (10%) 1 (8%) 
TIMI I 0 0 0 
TIMI II 0 1 (10%) 0 
TIMI II I  9 (100%) 8 (80%) 12 (92%) 
Dissections 
Absent 7 (78%) 5 (50%) 7 (53%) 
Type A 1 (11%) 1 (10%) 1 (8%) 
Type B 0 3 (30%) 4 (31%) 
Type C 1 (11%) 1 (10%) 0 
Type D 0 0 1 (8%) 
Thrombus post-PTCA 0 1 (10%) 0 
TIMI flow at 24 hrs 
TIMI 0 0 0 1 (8%) 
TIMI I 0 1 (12%) 0 
TIMI II 0 0 0 
TIMI II I  9 (100%) 7 (88%) 10 (84%) 
Not applicable 0 0 1 (8%) 
Categorical variables are presented in absolute values and percent 
N (%). 
Table 4. Occurrence of clinical events per dosage group 
Group B Group C Group D 
(N = 8) (N = 9) (N = 11) 
Death 
MI 
CABG 
Bail-out 
Repeat PTCA 
Any event 0 (0%) 
12-lead ECG ST 8 (100%) 
monitoring 
Patients with ST episodes - -  
Number of ST episodes b - -  
Duration of episodes 
(median in min: see) 
Bleeding complications 
Epistaxis 
False aneurysm 
Bleeding at puncture site 1 (13%) 
- -  1 (9%) 
2 (22%) - -  
- -  1 (9%) 
1 a (11%) 3 a (18%) 
3 (33%) 2 (18%) 
9 (100%) 11 (100%) 
1 (11%) 3 (27%) 
0.9 2.9 
2:33 32:07 
m 1 (9%) 
1 (9%) 
1 (9%) 
aThe repeat PTCA in group B and one repeat PTCA in group C was 
triggered by the recatheterization 24 hours after the start of the 
infusion. 
~bNormalized to 24 hours recording time during treatment. 
MI = myocardial infarction; CABG = coronary artery bypass graft 
surgery; PTCA = percutaneous transluminal coronary angiography. 
just i fy  solid conclusions on angiographic and clinical 
results.  Individual coagulation parameters  may yield 
specific information on the unstable syndrome or com- 
plexity of the lesion, but  this relat ionship remains 
speculative. 
Dose-response r lationship of argatroban 
plasma level and coagulation parameters 
The relat ionships between argatroban plasma level 
and coagulation parameters  (ACT, aPTT, TT, and PT) 
are presented in F igure  1. A clear dose-response r la- 
t ionship is documented for each parameter .  Table 5 
presents  the results  of l inear regress ion analysis. In- 
clusion of a squared variable in the model (e.g., y = 
a + bx + c 2) for TT improved the R-square value 
from 0.639 to 0.653. Addit ional  inclusion of a cubed 
variable (e.g., y = a + bx + c 2 + dx 3) in the aPTT 
model only marginal ly  improved the R-square value 
from 0.715 to 0.725. Al though these improvements in
the models for TT and aPTT are stat ist ical ly signifi- 
cant, we suggest  restr ict ion to the l inear and square 
models, respect ively,  for pragmat ic  reasons. Loga- 
r i thmic s t ra tegy  in the aPTT model resulted in an 
R-square value of 0.64 (p < 0.001), which is inferior 
to the square model. No clear relat ionship could be 
detected between the argatroban plasma level and F1. 2 
and TAT concentrations (F igure 2); however,  a sub- 
stantial  number of measurements  exceeded the nor- 
real range (1.29 nmol/1 for F1. 2 and 3.2 ~g/kg/1 for 
TAT). 
Discuss ion  
Argat roban was developed in Japan (Mitsubishi- 
Dachii), where authorizat ion for its use in the treat-  
ment of per ipheral  arter ia l  disease was obtained in 
1991 (MD-805, available as Novastan).  The rationale 
for this study was based on the finding that specific 
ant i thrombin therapies  can inhibit mural  thrombosis 
after deep arter ia l  in jury and prevent  the growth of 
pre-exist ing thrombus on deeply in jured arter ies ex- 
posed to both high and low shear stresses [8]. Exper i -  
mental ly,  in jured arter ies  remain highly thrombo- 
genic for several  hours to days following balloon 
injury [30-33]. Therefore,  it was judged prudent  to 
commence argatroban administrat ion before the an- 
gioplasty procedure and to continue over the next 72 
hours. The restr ict ion of argatroban to intravenous 
administrat ion l imits its use to hospital setting. 
The initial dosage was based on previous studies 
in cardiac pat ients.  Gold and his colleagues infused 
argatr0ban (0.5-5.0 ~g/kg/min)  over 4 hours in pa- 
t ients with unstable angina pectoris [24]. This dose 
regimen was effective against the recurrence of isch- 
emic episodes. F i tzgera ld  (not published) t reated an- 
g ioplasty pat ients with an initial bolus of 30 ~g/kg 
argatroban,  followed by an intravenous infusion of 2 
~g/kg/min over 2 hours. Based on toxicity studies in 
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Fig. 1. The relationship between argatroban plasma level and the result of coagulation tests. ACT = activated clotting time; 
aPTT = activated partial thromboplastin time; TT = thrombin time; PT  = prothrombin time. The lines within the graphs outline 
the predicted levels of the models delineated in Table 5. A: ACT  in seconds. B:  aPTT in seconds. C: TT in seconds (thrombin con- 
centration 20 IU/ml). D: PT  in seconds. 
Table 5. Relationship between coagulation parameters and 
argatroban plasma level 
R 
Parameter  Formula  p value square 
BT  - -  NS  0.00 
ACT 190 + 36.8 * APL  0.000 0.54 
aPTT  33.2 + 23.9 * APL  - 2.25 * APL  2 0.000 0.71 
TT 5.53 + 23.7 * APL  0.000 0.64 
PT  11.4 + 4.88 * APL  0.000 0.84 
APL  = Argat roban  p lasma level;  BT  = b leed ing  t ime;  ACT  = 
act ivated  coagu la t ion  t ime;  aPTT  = act ivated  par t ia l  th rombop las t in  
t ime;  TT  = thrombin  t ime;  PT  = prothrombin  t ime.  
animals, the total daily dose should not exceed 10 mg/ 
kg body weight. 
A significant correlation was observed between the 
Argatroban plasma level and the dose-response 
curves for several coagulation parameters. The pre- 
dictability of the aPTT and the PT, in particular, is 
very good and can be described mathematically with 
statistical significance. However, the predictability of
bleeding time is low. Measurements of ACT with the 
Hemochron system yields values approximately 30% 
higher than the results assessed with HemoTec ACT 
assessment [34], which may have influenced the R- 
square value. The dose-response curves of argatroban 
and coagulation tests demonstrate he feasibility of 
accurate dosing of this compound in contrast to hepa- 
rin, with which nonspecific plasma protein binding, 
variable bioavailability, nonlinear dose-dependent 
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Table 6A. Thrombin-antithrombin I I I  complex (normal range 0.60-3.20 p~g/L) by dosage group (median and range shown in 
brackets) 
Time N Group B N Group C N Group D 
-'/2 hr 8 4.1 (2.2-18.5) 9 2.6 (2.0-10.5) 11 3.9 (2.0-11.0) 
1 hr 8 4.0 (2.0-6.0) 9 2.7 (2.0-31.5) 11 3.3 (2.0-17.0) 
2 hr 7 5.0 (2.4-12.0) 8 2.3 (2.0-4.2) 11 4.8 (2.4-161.0) 
24 hr 8 5.7 (4.5-20.0) 7 5.0 (4.0-6.8) 9 8.0 (4.3-52.5) 
72 hr 7 3.2 (2.4-13.0) 7 2.6 (2.0-4.2) 8 3.8 (2.9-11.0) 
73 hr 7 4.8 (2.3-28.0) 7 3.0 (2.0-6.3 8 5.5 (2.2-36.0) 
74 hr 7 4.3 (3.2-125.0) 7 3.6 (2.0-13.0) 8 5.0 (2.0-10.6) 
Table 6B. Prothrombin fragments 1 and 2 (normal range 0.57-1.29 nmol/L) by dosage group (median and range shown in 
brackets) 
Time N Group B N Group C N Group D 
-'/2 hr 8 0.93 (0.43-2.10) 9 1.10 (0.45-1.50) 11 1.30 (0.55-3.40) 
1 hr 8 0.76 (0.50-1.30) 9 1.10 (0.80-3.20) 11 1.80 (0.90-3.40) 
2 hr 7 1.30 (0.60-2.20) 8 1.35 (0.90-2.20) 11 2.00 (0.60-7.00) 
24 hr 8 1.80 (0.95-3.80) 7 1.90 (1.45-2.60) 9 2.90 (0.85-4.00) 
72 hr 7 0.70 (0.47-1.05) 7 1.05 (0.90-1.30) 8 1.35 (0.85-2.10) 
73 hr 7 0.95 (0.65-2.20) 7 0.95 (0.70-1.30) 8 1.45 (0.75-5.00) 
74 hr 7 1.00 (0.70-11.25) 7 0.90 (0.62-1.80) 8 1.13 (0.34-2.50) 
clearance, and important individual differences among 
patients frequently result in underdosing or over- 
dosing. 
Levels of F1. 2 and TAT reflect the degree of pro- 
thrombin conversion and thrombin activity, respec- 
tively. Sampling was performed from separate periph- 
eral vein punctures to avoid bias caused by the 
indwelling catheter [35,36]. These measurements indi- 
cate the systemic status of the coagulation system. 
Sampling from the great cardiac vein may have been 
more accurate, representing a less diluted effect on 
the local stimulus to the coagulation system. Absolute 
inhibition of thrombin generation by thrombin block- 
ade remains a utopian concept, since argatroban re- 
quires an insignificant prothrombin conversion before 
it can display its antithrombin activity. Zoldhelyi et al. 
[37] recently reported their failure to block thrombin 
generation i  patients, despite a 10,000-fold molar ex- 
cess of free hirudin over the thrombin-hirudin com- 
plex. Furthermore, these coagulation products are ex- 
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Fig. 3. The results ofF1. 2 and TAT and measurements re- 
lated to the infusion period. A: F1. 2 in nmol/l. B: TAT in 
p~g/l. 
tremely sensitive, to such an extent hat only perfect 
atraumatic vein punctures can provide blood with un- 
affected, nonelevated levels. 
Conceivably, a superior marker for thrombin block- 
ade would be the fibrino-peptide A concentration [38]. 
This peptide is a product of thrombin-induced fibrino- 
gen conversion and is therefore a direct mirror of the 
performance of nonblocked thrombin. 
Rebound is described after cessation of IV argatro- 
ban infusion in patients with unstable angina pectoris 
[24,39]. In this study we did not uncover any clinical 
evidence for a rebound phenomenon i this cohort of 
patients. However, 24 hours after start of the infusion 
(just prior to sheath removal when the infusion was 
transiently interrupted), a substantial elevation of 
TAT and F1. 2 levels was observed (Table 6; Figure 3). 
A lesser increase in TAT and F1. 2 levels was detected 
1 and 2 hours after the termination of the argatroban 
infusion (73 and 74 hours after the start of the infu- 
sion, respectively). This disparate response to cessa- 
tion of argatroban administration may reflect he pro- 
cess of vessel wall passivation. It has to be 
emphasized that repetitive vein punctures within a 
short period of time may result in subsequent less 
optimal sampling quality, and therefore may demon- 
strate artifically elevated levels of TAT and F1. 2. 
Conc lus ions  
This dose-finding study demonstates that argatroban 
infusion in patients undergoing PTCA may be safely 
administered, and produces an adequate and predict- 
able level of anticoagulation. This trial provides useful 
and consistent information on the response of the co- 
agulation system when exposed to argatroban. Indi- 
rect paramaters indicate ongoing thrombin conversion 
(prothrombin fragments 1 and 2) and activity (throm- 
bin-antithrombin complex). An apparent safe and ad- 
equate dosage regimen was identified, and this dose is 
now undergoing further evaluation in a double-blind, 
double-dummy, 2:1 randomized and heparin- 
controlled study. The effect of argatroban on the re- 
stenosis process following coronary angioplasty must 
be determined in a larger investigation. 
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